


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the March 2014 NCCN Trends™ Survey, which focused on Liver Cancer. This survey was sent to U.S. and International users of NCCN.org.


DEMOGRAPHICS

Distribution of Respondent Types (n = 581)




Note: Percentages may not total 100 because of rounding.

Q1. Do you treat patients with liver cancer? (n = 511)




Q2. Based on your knowledge, what types of data support the use of locoregional therapy for unresectable primary and secondary liver cancer? (check all that apply) (n = 291)



Q2. Based on your knowledge, what types of data support the use of locoregional therapy for unresectable primary and secondary liver cancer? (check all that apply)

By Geography


- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US



Q2. Based on your knowledge, what types of data support the use of locoregional therapy for unresectable primary and secondary liver cancer? (check all that apply)


By Practice Size

- 1 to 3
- 4 to 9
- 10 or more



Q2. Based on your knowledge, what types of data support the use of locoregional therapy for unresectable primary and secondary liver cancer? (check all that apply)


By Practice Setting




Q2. Based on your knowledge, what types of data support the use of locoregional therapy for unresectable primary and secondary liver cancer? (check all that apply)

By Specialty

- Medical Oncology
- Radiation Oncology
- Surgical Oncology
- Internal Medicine
- General Surgery
- Other




Q3. With regard to hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC), how knowledgeable are you of the treatment devices/ procedures that are used as locoregional therapy? (n = 286)



Q3. With regard to hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC), how knowledgeable are you of the treatment devices/procedures that are used as locoregional therapy?

By Geography


- Not at all knowledgeable
- Slightly knowledgeable
- Somewhat knowledgeable
- Very knowledgeable
- Extremely knowledgeable



Q3. With regard to hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC), how knowledgeable are you of the treatment devices/procedures that are used as locoregional therapy?

By Practice Size


- Not at all knowledgeable
- Slightly knowledgeable
- Somewhat knowledgeable
- Very knowledgeable
- Extremely knowledgeable



Q3. With regard to hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC), how knowledgeable are you of the treatment devices/procedures that are used as locoregional therapy?

By Practice Setting


- Not at all knowledgeable
- Slightly knowledgeable
- Somewhat knowledgeable
- Very knowledgeable
- Extremely knowledgeable




Q3. With regard to hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC), how knowledgeable are you of the treatment devices/procedures that are used as locoregional therapy?

By Specialty

- Not at all knowledgeable
- Slightly knowledgeable
- Somewhat knowledgeable
- Very knowledgeable
- Extremely knowledgeable




Q4. To what extent do the following types of trials influence your support of locoregional therapy for primary and secondary liver cancer? (n = 272)



Q4. To what extent do the following types of trials influence your support of locoregional therapy for primary and secondary liver cancer?

By Geography


- Not at all influential
- Slightly influential
- Somewhat influential
- Very influential
- Extremely influential



Q4. To what extent do the following types of trials influence your support of locoregional therapy for primary and secondary liver cancer?

By Practice Size


- Not at all influential
- Slightly influential
- Somewhat influential
- Very influential
- Extremely influential



Q4. To what extent do the following types of trials influence your support of locoregional therapy for primary and secondary liver cancer?

By Practice Setting


- Not at all influential
- Slightly influential
- Somewhat influential
- Very influential
- Extremely influential




Q4. To what extent do the following types of trials influence your support of locoregional therapy for primary and secondary liver cancer?

By Specialty

- Not at all influential
- Slightly influential
- Somewhat influential
- Very influential
- Extremely influential




Q5. Which of these liver directed therapies do you recommend for patient management? (check all that apply) (n = 275)



Q5. Which of these liver directed therapies do you recommend for patient management? (check all that apply)



By Geography

- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US



Q5. Which of these liver directed therapies do you recommend for patient management? (check all that apply)


By Practice Size



Q5. Which of these liver directed therapies do you recommend for patient management? (check all that apply)


By Practice Setting

■ Academic Setting
■ Community Setting



Q5. Which of these liver directed therapies do you recommend for patient management? (check all that apply)

By Specialty



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.org/patients - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.